anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Systemic inflammation elicits sickness behaviors and fever by engaging a complex neuronal circuitry that begins in the preoptic area of the hypothalamus. Ectotherms such as teleost fish display sickness behaviors in response to infection or inflammation, seeking warmer temperatures to enhance survival via behavioral fever responses. To date, the hypothalamus is the only brain region implicated in sickness behaviors and behavioral fever in teleosts. Yet, the complexity of neurobehavioral manifestations underlying sickness responses in teleosts suggests engagement of higher processing areas of the brain. Using in vivo models of systemic inflammation in rainbow trout, we find canonical pyrogenic cytokine responses in the hypothalamus whereas in the telencephalon and the optic tectum il-1b and tnfa expression is decoupled from il-6 expression. Polyamine metabolism changes, characterized by accumulation of putrescine and decreases in spermine and spermidine, are recorded in the telencephalon but not hypothalamus upon systemic injection of bacteria. While systemic inflammation causes canonical behavioral fever in trout, blockade of bacterial polyamine metabolism prior to injection abrogates behavioral fever, polyamine responses, and telencephalic but not hypothalamic cytokine responses. Combined, our work identifies the telencephalon as a neuronal substrate for brain responses to systemic inflammation in teleosts and uncovers the role of polyamines as critical chemical mediators in sickness behaviors.
The present invention relates to a method for extracting the oleaginous substances from sporoderm-broken Ganoderma spores using SCF-CO2. The method contains the steps of breaking the Ganoderma spores by a mechanical means to obtain the sporoderm-broken spores; and extracting the oleaginous substances from the sporoderm-broken spores using a supercritical fluid - carbon dioxide (SCF-CO2) extraction method. Before breaking the spores by a mechanical means, there may be steps of inducing germination of Ganoderma spores by incubating the spores in a nutritional solution and activating the Ganoderma spores by placing the germination-induced spores in a well ventilated culture box kept at constant temperature and humidity to obtain the sporoderm-broken spores. As for SCF-CO2, the preferred supercritical conditions include 5 M to 60 M Pa of pressure; 32 DEG C to 85 DEG C of temperature; and 5 kg/h to 80 kg/h of flow capacity rate. The total extraction time in SCF-CO2 is between 0.5 hour to 6 hour. The method produces approximately 37% by weight of oleaginous substances from the sporoderm-broken Ganoderma spores. These oleaginous substances are transparent and contain the special fragrance of Ganoderma spores. There is no trace of deposit, solvent residue, or oxidization in the oleaginous substances.
Cultural exchange of fermentation techniques has driven the spread of Saccharomyces cerevisiae across the globe, establishing natural populations in many countries. Despite this, Oceania is thought to lack native populations of S. cerevisiae, only being introduced after colonisation. Here we investigate the genomic landscape of 411 S. cerevisiae isolated from spontaneous grape fermentations in Australia across multiple locations, years, and grape cultivars. Spontaneous fermentations contained highly recombined mosaic strains that exhibited high levels of genome instability. Assigning genomic windows to putative ancestral origin revealed that few closely related starter lineages have come to dominate the genetic landscape, contributing most of the genetic variation. Fine-scale phylogenetic analysis of loci not observed in strains of commercial wine origin identified widespread admixture with European derived beer yeast along with three independent admixture events from potentially endemic Oceanic lineages that was associated with genome instability. Finally, we investigated Australian ecological niches for basal isolates, identifying phylogenetically distinct S. cerevisiae of non-European, non-domesticated origin associated with admixture loci. Our results illustrate the effect commercial use of microbes may have on local microorganism genetic diversity and demonstrates the presence of non-domesticated, potentially endemic lineages of S. cerevisiae in Australian niches that are actively admixing.
The invention relates to Iodes vitiginea (Hance)Hemsl. wine and its preparation method and belongs to the technology of traditional Chinese medicine. Pharmacodynamic components of the Iodes vitiginea (Hance)Hemsl. wine are prepared from Iodes vitiginea (Hance)Hemsl., balsamiferou blumea herb and liquor. The Iodes vitiginea (Hance)Hemsl. wine disclosed in the invention has effects of expelling wind and removing cold and eliminating dampness and dredging channels, and mainly treats wind-cold-wetness bype of arthralgia, nephritis and lumbar muscle degeneration.
The invention relates to a monoclonal antibody targeting CD47 and application thereof. The monoclonal antibody comprises: a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises three complementarity determining regions: the light chain variable region comprises three complementarity determining regions, HCDR1 having the amino acid sequence of SEQ ID NO. 5, HCDR2 having the amino acid sequence of SEQ ID NO. 6, and HCDR3 having the amino acid sequence of SEQ ID NO. 7: LCDR1 with the amino acid sequence of SEQ ID NO. 8, LCDR2 with the amino acid sequence of SEQ ID NO. 9 and LCDR3 with the amino acid sequence of SEQ ID NO. 10. The monoclonal antibody is combined on a brand-new epitope of the CD47 protein, and shows good safety, particularly blood safety, while showing good combination and blocking activity with the CD 47.
PURPOSE:To effectively obtain amylase inhibitor T-76 by cultivating a bacterium belonging to the genus Streptomyces. CONSTITUTION:A bacterium (e.g., Streptomyces nitrosporeus) belonging to the genus Streptomyces is cultivated to give amylase inhibitor T-76 having the following properties. Action: inhibiting human pancreatic amylase, human salivary amylase and swine pancreatic amylase but not alpha-amylase derived from a bacterium belonging to the genus Bacillus, beta-amylase of soybean, beta-amylase of barley, glucoamylase derived from a fungus belonging to the genus Rhizopus, isoamylase derived from a bacterium belonging to the genus Pseudomonas, pepsin, trypsin and alpha-chymotrypsin. Stable pH range and thermostability: stable for 24hours at pH3-12 at 30 deg.C and stable for 15minutes at pH3-9 at 100 deg.C. Molecular weight: about 1,800 by SDS-polyacrylamide gel electrophoresis. Isoelectric point: 3.8 isoelectric point using Ampholine as a carrier. Ultraviolet light spectrum: maximum absorption at 278nm and minimum absorption at 250nm.
Axial motor dysfunctions in Parkinson disease (PD) are least responsive to dopaminergic therapy and incline many patients towards a sedentary lifestyle. This places PD patients at increased risk for the negative consequences of physical inactivity. When PD patients develop postural imbalance and gait difficulties, including falls, they are generally referred to physical therapy for optimal management. Although these patients do benefit from physical therapy, there is a critical gap in clinical practice on what to do next once the physical therapy sessions are over. Clinical experience shows that most patients return to a sedentary lifestyle indicating an urgent need for post-physical therapy in-home physical activity programs in PD with postural imbalance and gait difficulties to preserve mobility functions. Recent advances in physical activity research tout non-exercise physical activity approaches to promote healthy lifestyle modifications. Non-exercise physical activities are activities of daily living, like cleaning, shopping, and standing, other than intentional exercise. For PD patients with postural imbalance and gait difficulties, normal upright standing and weight-shifting (stepping) for longer periods of time may be an ideal form of non-exercise physical activity. It activates lower extremity muscles and encourages postural activity. To promote this type of non-exercise physical activity, the study team applies a "dynamic standing table", which periodically cues users to make steps. Dynamic standing would represent a minimal level of physical activity compared to sitting, which is pervasive in PD subjects with postural imbalance and gait difficulties. Use of the dynamic standing table can easily be incorporated with routine desktop activities, such as computer use, reading, or watching TV and may promote physical activity. The purpose of this study is to determine whether a post-physical therapy in-home physical activity program using the dynamic standing table (as an adjunct to post-physical therapy standard of care-weekly physical activity group sessions) is effective in sustaining the mobility benefits of physical therapy compared with post-physical activity standard of care alone in individuals with Parkinson disease and postural imbalance and gait difficulties. The study team is testing the exploratory hypothesis that post-physical therapy gains in mobility functions in PD patients with postural imbalance and gait difficulties will be preserved better with in-home dynamic standing table use compared to a control group. After consulting with regulatory specialists, this device was determined to be 510k exempt and falls under part 890 Physical Medicine devices Subpart F- Physical Medicine therapeutic devices. Sec. 890.5370 Nonmeasuring exercise equipment.
Internet-based self-management program Patients randomized to active treatment intervention will be assigned to the Internet program. The site will be accessed via secured website. The modules will be presented 1-2 per week and will be moderated by a researcher with expertise in moderating Discussion Boards.
FIELD: applied biochemistry. SUBSTANCE: method involves an acid treatment of tissue extract and ion-exchange chromatography. This provides a significant increase of enzymes yield (up to 130-160%) that exceeds the total activity determined in an extract. Repeated centrifugations of large liquid volumes are excluded. EFFECT: improved and simplified method of isolation, diminished laboriousness of procedure. 1 tbl, 1 ex
Constipation during pregnancy can induce serious complications, including miscarriage and preterm labour, while the evidence of probiotics in improving constipation during pregnancy was little. In this study, 29 healthy pregnant women and 65 constipated pregnant women were enrolled to assess the effectiveness of probiotics on constipation during pregnancy. Our results showed that the probiotics were effective in improving the Constipation Severity Scale (CSS) and Bristol Stool Scale (BSS) scores, including increasing defecation frequency, decreasing defecation time, and improving fecal characteristics. 16S rRNA sequencing revealed that the probiotics effectively restored the diversity of intestinal microbiota. At the phylum level, Firmicutes (13.27% vs 57.20%) and Actinobacteria (3.77% vs 12.80%) were increased, while Bacteroidetes (77.82% vs 20.24%) was decreased. At the level of the genus, Faecalibacterium (2.03% vs 10.33%), Bifidobacterium (1.21% vs 8.56%), and Phascolarctobacterium (0.05% vs 2.88%), the beneficial bacteria were increased, while the Bacteroides (29.23% vs 12.28%) and Prevotella (24.32% vs 4.92%) were decreased. In conclusion, these results indicated that probiotics can effectively relieve the constipation symptoms by improving the diversity of intestinal microbiota, regulating the disturbance of microflorae, and restoring the balance of microflorae to exert a stronger moderating effect than diet and lifestyle modification. Our results provided clinical data and a theoretical basis for the exploitation of probiotics in treating constipation during pregnancy. Chinese Clinical Trial Registry: ChiCTR2100052069.
PROBLEM TO BE SOLVED: To obtain the subject composition capable of not only assisting the digestion but also manifesting excellent improving actions on the gastric emptying ability and useful as an improving agent and therapeutic agent for complaint about an alimentary canal by formulating a lipase preparation which is a digestive enzyme. SOLUTION: This composition is obtained by formulating a lipase preparation as an active ingredient. A usually commercially available lipase for medical use (especially preferably a microorganism-derived lipase) can be used as the lipase preparation; however, an enzyme preparation having a fat digesting power as a main digesting power is more preferred. One or more kinds of ingredients selected from an improving agent for enterokinesis, an antagonist of a histamine H2 receptor, a proton pump inhibitor and an ingredient having stomachic actions and capable of acting on an alimentary canal are preferably contained in the composition.  Thereby, the composition can be expected as an improving agent for the gastric emptying ability having improving actions on a delay of the gastric emptying and capable of reducing the complaint about the alimentary canal (e.g. chronic gastrointestinal symptoms such as a feeling of heaviness or a load on the stomach) and normalizing the dysfunction of the alimentary canal.
Twenty patient will be enrolled into this arm. Enteral nutrition administration will start within 24 hours after admission through naso-jejunal tube and continue for 7 days after admission.Naso-jejunal tube will be set up by endoscopy.
Clinically significant hyponatremia (sodium <125 mmol/L) may develop during Oxtellar XR use. Serum sodium levels less than 125 mmol/L have occurred in immediate-release oxcarbazepine-treated patients generally in the first three months of treatment. However, clinically significant hyponatremia may develop more than a year after initiating therapy.

Most immediate-release oxcarbazepine-treated patients who developed hyponatremia were asymptomatic in clinical trials. However, some of these patients had their dosage reduced, discontinued, or had their fluid intake restricted for hyponatremia. Serum sodium levels returned toward normal when the dosage was reduced or discontinued, or when the patient was treated conservatively (e.g., fluid restriction). Cases of symptomatic hyponatremia and syndrome of inappropriate antidiuretic hormone secretion (SIADH) have been reported during post-marketing use of immediate-release oxcarbazepine.

Among treated patients in a controlled trial of adjunctive therapy with Oxtellar XR in 366 adults with complex partial seizures, 1 patient receiving 2400 mg experienced a severe reduction in serum sodium (117 mEq/L) requiring discontinuation from treatment, while 2 other patients receiving 1200 mg experienced serum sodium concentrations low enough (125 and 126 mEq/L) to require discontinuation from treatment. The overall incidence of clinically significant hyponatremia in patients treated with Oxtellar XR was 1.2%, although slight shifts in serum sodium concentrations from Normal to Low (<135 mEq/L) were observed for the 2400 mg (6.5%) and 1200 mg (9.8%) groups compared to placebo (1.7%).

Measure serum sodium concentrations if patients develop symptoms of hyponatremia (e.g., nausea, malaise, headache, lethargy, confusion, obtunded consciousness, or increase in seizure frequency or severity). Consider measurement of serum sodium concentrations during treatment with Oxtellar XR, particularly if the patient receives concomitant medications known to decrease serum sodium levels (for example, drugs associated with inappropriate ADH secretion).
The present invention relates to a cosmetic, more specifically to a Chinese medicine fluid for spot elimination and skin beautification, and a preparation method thereof. At present, pox elimination cosmetics sold in the market have inconspicuous pox elimination effect, or the components of ethanol, oxybenzoic acid, antibiotic, etc. contained in the cosmetics have great irradiation to skin, so the cosmetics are difficult to be accepted by customers. In the Chinese medicine fluid, the Chinese medicine aqua fluid which is used for pox elimination and beautification, has high curative effect, and contains no ethanol, oxybenzoic acid or bacteriophage is developed. The preparation method comprises: taking water as a solvent; putting sunset abelmoschus root, liquorice, wild chrysanthemum, honeysuckle and milk vetch into the water; heating the water to decoct the components for a certain period for leaching; collecting leach fluid. The Chinese medicine fluid has no irritation to skin, has no toxic or side effect, has the functions of eliminating heat and toxin, relieving inflammation and restraining bacteria, and is capable of effectively breaking down the toxin of acne bacteria, preventing red vestiges left by acne, balancing sebum excretion, shrinking pores, improving skin quality, postponing wrinkle formation and making skin smooth and fine.
For patients with transfusional iron overload, measure serum ferritin monthly to assess the patient’s response to therapy and minimize the risk of overchelation. An analysis of pediatric patients treated with deferasirox tablets for oral suspension in pooled clinical trials (n = 158), found a higher rate of renal adverse reactions among patients receiving doses greater than 25 mg/kg/day equivalent to 17.5 mg/kg/day deferasirox while their serum ferritin values were less than 1,000 mcg/L. Consider dose reduction or closer monitoring of renal and hepatic function, and serum ferritin levels during these periods. Use the minimum effective dose to maintain a low-iron burden [see Adverse Reactions (6.1), Use in Specific Populations (8.4)].

If the serum ferritin falls below 1,000 mcg/L at 2 consecutive visits, consider dose reduction, especially if the deferasirox dose is greater than 17.5 mg/kg/day [see Adverse Reactions (6.1)]. If the serum ferritin falls below 500 mcg/L, interrupt therapy with deferasirox and continue monthly monitoring. Evaluate the need for ongoing chelation for patients whose conditions do not require regular blood transfusions. Use the minimum effective dose to maintain iron burden in the target range. Continued administration of deferasirox in the 14 to 28 mg/kg/day range, when the body iron burden is approaching or within the normal range can result in life-threatening adverse reactions [see Dosage and Administration (2.1)].

For patients with NTDT, measure LIC by liver biopsy or by using an FDA-cleared or approved method for monitoring patients receiving deferasirox therapy every 6 months on treatment. Interrupt deferasirox administration when the LIC is less than 3 mg Fe/g dw. Measure serum ferritin monthly, and if the serum ferritin falls below 300 mcg/L, interrupt deferasirox and obtain a confirmatory LIC [see Clinical Studies (14)].
Infliximab and 6-MP will be added to patients with a SCCAI greater than 2 at week 8. The first infusion of infliximab (5 mg/kg) will be given during that week. In addition, 6-MP will be initiated at doses of 1.0-1.5 mg/kg PO QD to reduce the incidence of infliximab antibody formation and facilitate steroid tapering (the target dose of 6-MP will be decreased accordingly if patients are found to have low TMPT levels/activity by genotypic or phenotypic testing). Also, steroids will also be rapidly tapered off at this time.
Provided are antibodies that specifically bind human astrovirus (HAstV) capsid spike protein. Fusion proteins and conjugates comprising such antibodies are also provided. Also provided are nucleic acids that encode one or both of the variable chain polypeptides of an antibody of the present disclosure, as are cells that include such nucleic acids. Also provided are compositions that include the antibodies of the present disclosure, including in some instances, pharmaceutical compositions. Methods of making and using the antibodies of the present disclosure are also provided. In certain aspects, provided are methods that include administering to an individual having or suspected of having a HAstV infection a therapeutically effective amount of an antibody, fusion protein or conjugate of the present disclosure.
In this study, a WSTM TY101 FIR emitter (WS Far Infrared Medical Technology Co., Ltd., Taipei, Taiwan) will be used for FIR therapy. The electrified ceramic plates of this emitter generate electromagnetic waves with wavelengths in the range between 3 and 25 μm (a peak between 5 to 6 μm). The irradiating power density is 10 and 20 mili watt\<mw\>/cm2 when the top radiator is set at a distance between 30 and 20 cm above the skin surface respectively. In this study, the top radiator will be set at a height of 25 cm above the surface of bilateral lower legs and the treatment time will be set at 40 minutes for patients on maintenance HD.
In a U.S. multicenter, double-blind, placebo-controlled, dose-response (15, 30, and 60 mg of lansoprazole once daily) study of 284 patients with endoscopically documented duodenal ulcer, the percentage of patients healed after two and four weeks was significantly higher with all doses of lansoprazole than with placebo. There was no evidence of a greater or earlier response with the two higher doses compared with lansoprazole 15 mg. Based on this study and the second study described below, the recommended dose of lansoprazole in duodenal ulcer is 15 mg per day (Table 9). 

Lansoprazole 15 mg was significantly more effective than placebo in relieving day and nighttime abdominal pain and in decreasing the amount of antacid taken per day.

In a second U.S. multicenter study, also double-blind, placebo-controlled, dose-comparison (15 and 30 mg of lansoprazole once daily), and including a comparison with ranitidine, in 280 patients with endoscopically documented duodenal ulcer, the percentage of patients healed after four weeks was significantly higher with both doses of lansoprazole than with placebo. There was no evidence of a greater or earlier response with the higher dose of lansoprazole. Although the 15 mg dose of lansoprazole was superior to ranitidine at four weeks, the lack of significant difference at two weeks and the absence of a difference between 30 mg of lansoprazole and ranitidine leaves the comparative effectiveness of the two agents undetermined (Table 10) [see Indications and Usage (1.1)] .
Snake venoms are a complex mixture of proteins and polypeptides that represent a valuable source of potential molecular tools for understanding physiological processes for the development of new drugs. In this study two major PLA2s, named PLA2-I (Asp49) and PLA2-II (Lys49), isolated from the venom of Bothrops diporus from Northeastern Argentina, have shown cytotoxic effects on LM3 murine mammary tumor cells, with PLA2-II-like exhibiting a stronger effect compared to PLA2-I. At sub-cytotoxic levels, both PLA2s inhibited adhesion, migration, and invasion of these adenocarcinoma cells. Moreover, these toxins hindered tubulogenesis in endothelial cells, implicating a potential role in inhibiting tumor angiogenesis. All these inhibitory effects were more pronounced for the catalytically-inactive toxin. Additionally, in silico studies strongly suggest that this PLA2-II-like myotoxin could effectively block fibronectin binding to the integrin receptor, offering a dual advantage over PLA2-I in interacting with the αVβ3 integrin. In conclusion, this study reports for the first time, integrating both in vitro and in silico approaches, a comparative analysis of the antimetastatic and antiangiogenic potential effects of two isoforms, an Asp49 PLA2-I and a Lys49 PLA2-II-like, both isolated from Bothrops diporus venom.
All eligible patients with Chronic Obstructive Pulmonary Disease (COPD) grade 1 according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) were included in this group. The observational period is 156 weeks.